PALO ALTO, California, April 13 /PRNewswire/ --
Cell Biosciences, Inc., a provider of nanoproteomic analysis systems to life science researchers, today announced the publication of a landmark study by a research team from Stanford University School of Medicine. Dr. Dean W. Felsher, Associate Professor of Oncology, was senior author on the study. The publication, titled Nano-fluidic proteomic assay for serial analysis of oncoprotein activation in clinical samples, appeared on April 12, 2009 as an Advance Online Publication in the prestigious journal Nature Medicine. In this work, the authors report on new methods for detecting small modifications in cancer-related proteins. Importantly, the exceptional sensitivity of the methods enabled oncoprotein studies in extremely small tumor samples derived from cancer patients. This work was performed using a protein analysis system from Cell Biosciences.
Current protein research methods have difficulty detecting subtle changes in oncoprotein activation, changes that underlie critical cancer signaling processes, explained lead author Dr. Alice Fan. To develop new therapeutics for cancer, we need better tools for understanding the intricate control mechanisms within cancer cells. This novel nanofluidic technology is incredibly exciting because it enables us to measure cancer proteins that could not be feasibly measured before in limited patient samples.
Due to its unique nanofluidic design, the Cell Biosciences system uses exceptionally small test samples - the authors report using only 4 nanoliters per test. The extremely high detection sensitivity of our system is enabling a whole host of new experimental methods for cancer researchers, said Tim Harkness, President and CEO of Cell Biosciences. It is gratifying to see the adoption of our technology by cutting-edge researchers like the Stanford team.
The Cell Biosciences protein analysis system is an ultrasensitive nanofluidic immunoassay system designed to analyze extremely small biological samples. Traditional protein analysis techniques can require as many as 100,000 cells, which complicates protein analysis in limited samples. The Cell Biosciences system can measure cell signaling proteins reproducibly in as few as 25 cells.
About Cell Biosciences
Cell Biosciences is a private life sciences company focused on nanoproteomics. We develop instrumentation systems, software, and assay products that reveal previously undetectable information about cellular control pathways. Our customers include leading institutions in the fields of cancer research, stem cell biology, and diabetes. Our products enable researchers to uncover fundamental mechanisms controlling cell proliferation and cell death, to accelerate the development of new therapeutics, and to help identify new prognostic and diagnostic disease biomarkers. Cell Biosciences is located in Palo Alto, California. For more information, visit www.cellbiosciences.com.
Walter Ausserer, Ph.D., Vice President of Marketing of Cell Biosciences, Inc., +1-650-618-7503, email@example.com